PL2985026T3 - Farmaceutyczne systemy dostarczania leków hydrofobowych i zawierające je kompozycje - Google Patents

Farmaceutyczne systemy dostarczania leków hydrofobowych i zawierające je kompozycje

Info

Publication number
PL2985026T3
PL2985026T3 PL15186752.0T PL15186752T PL2985026T3 PL 2985026 T3 PL2985026 T3 PL 2985026T3 PL 15186752 T PL15186752 T PL 15186752T PL 2985026 T3 PL2985026 T3 PL 2985026T3
Authority
PL
Poland
Prior art keywords
compositions
same
delivery systems
hydrophobic drugs
pharmaceutical delivery
Prior art date
Application number
PL15186752.0T
Other languages
English (en)
Inventor
Robert Dudley
Panayiotis Constantinides
Original Assignee
Clarus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2985026(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Clarus Therapeutics, Inc. filed Critical Clarus Therapeutics, Inc.
Publication of PL2985026T3 publication Critical patent/PL2985026T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PL15186752.0T 2005-04-15 2006-04-14 Farmaceutyczne systemy dostarczania leków hydrofobowych i zawierające je kompozycje PL2985026T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67145405P 2005-04-15 2005-04-15
US72197105P 2005-09-30 2005-09-30

Publications (1)

Publication Number Publication Date
PL2985026T3 true PL2985026T3 (pl) 2023-02-20

Family

ID=37115755

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15186752.0T PL2985026T3 (pl) 2005-04-15 2006-04-14 Farmaceutyczne systemy dostarczania leków hydrofobowych i zawierające je kompozycje

Country Status (14)

Country Link
US (18) US8241664B2 (pl)
EP (3) EP2979699A1 (pl)
JP (3) JP5887044B2 (pl)
KR (3) KR101432466B1 (pl)
AU (2) AU2006236564B2 (pl)
BR (1) BRPI0607549A2 (pl)
CA (1) CA2604943C (pl)
DK (1) DK2985026T3 (pl)
ES (1) ES2930658T3 (pl)
HU (1) HUE061300T2 (pl)
PL (1) PL2985026T3 (pl)
PT (1) PT2985026T (pl)
RU (2) RU2623206C2 (pl)
WO (1) WO2006113505A2 (pl)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US8883769B2 (en) 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2006113505A2 (en) 2005-04-15 2006-10-26 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
SI1937276T1 (sl) 2005-10-12 2013-04-30 Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road Izboljšani testosteronski gel in postopek uporabe
CA2882048C (en) 2006-02-03 2020-03-24 Opko Renal, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
CA2683514C (en) 2007-04-25 2019-07-09 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
JP5501224B2 (ja) 2007-05-25 2014-05-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 治療薬の経口投与のための製剤および関連する方法
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
KR101685031B1 (ko) 2008-04-02 2016-12-09 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20140288039A1 (en) * 2009-01-08 2014-09-25 Lipocine Inc. Lipobalanced long chain testosterone prodrugs for oral delivery
US20130225544A1 (en) * 2009-01-08 2013-08-29 Lipocine Inc. Lipobalanced long chain testosterone esters for oral delivery
WO2011050457A1 (en) * 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
CN102711741A (zh) * 2009-11-09 2012-10-03 比利时胶囊公司 递送载体
US20130122097A1 (en) * 2009-12-22 2013-05-16 Hallux, Inc. Antifungal therapy
PL2519230T3 (pl) * 2009-12-31 2019-05-31 Marius Pharmaceuticals Llc Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
CN103037902A (zh) 2010-03-29 2013-04-10 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
SG184540A1 (en) * 2010-04-12 2012-11-29 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
RU2642244C2 (ru) * 2010-04-12 2018-01-24 Кларус Терапеутикс, Инк. Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием
AU2014265072B2 (en) * 2010-04-12 2016-09-15 Besins Healthcare Luxembourg S.A.R.L. Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
CA2818491A1 (en) 2010-11-18 2012-05-24 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120135074A1 (en) * 2010-11-30 2012-05-31 Chandrashekar Giliyar High-Strength Testosterone Undecanoate Compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130309217A1 (en) * 2011-01-31 2013-11-21 Lucolas-M.D. Ltd. Cosmetic use
US11850451B2 (en) 2011-01-31 2023-12-26 Lucolas-M.D. Ltd. Cosmetic compositions and methods for improving skin conditions
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9364487B2 (en) * 2011-11-04 2016-06-14 Agile Therapeutics, Inc. Dermal delivery compositions and methods
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
DE102013111531A1 (de) 2012-10-18 2014-04-24 Electronics And Telecommunications Research Institute Vorrichtung zur raumfilterung unter verwendung eines sendeverzögerungsunterschieds von signalen und verfahren für selbiges
EP2934591B1 (en) 2012-12-20 2017-08-09 Solural Pharma Aps Solid oral dosage form of testosterone derivative
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2014222389B2 (en) * 2013-02-28 2018-11-29 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
EP2968886A1 (en) 2013-03-14 2016-01-20 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
CN105188670B (zh) 2013-03-15 2018-11-02 马留斯医药有限责任公司 乳液制剂
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US9040034B2 (en) 2013-04-09 2015-05-26 International Business Machines Corporation Vitamin functionalized gel-forming block copolymers for biomedical applications
US10245273B2 (en) * 2013-12-26 2019-04-02 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents
PT3096625T (pt) 2014-01-20 2020-05-20 Xeda International Composições anti-germinativas para revestir bolbos e tubérculos e sua utilização para tratamento anti-germinativo
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3157505B1 (en) * 2014-06-17 2019-07-24 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
EP3157508B1 (en) 2014-06-19 2020-12-09 Solural Pharma Aps Solid oral dosage form of lipophilic compounds
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP2017529339A (ja) * 2014-08-28 2017-10-05 リポカイン インコーポレーテッド 医薬組成物および方法
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
DK3185872T3 (da) 2014-08-28 2021-06-21 Univ Texas Formulering af testosteron og metoder til behandling hermed
JP6948660B2 (ja) 2014-11-13 2021-10-13 東亞合成株式会社 外来物質の細胞内への導入方法ならびに該方法に用いる材料
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3804698B1 (en) 2015-08-03 2024-01-31 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
KR101679380B1 (ko) 2015-09-10 2016-11-25 주식회사 유유제약 두타스테리드를 포함하는 약학적 조성물 및 이를 포함하는 캡슐 제형
JP6097803B2 (ja) * 2015-09-17 2017-03-15 クラルス セラピューティクス，インク． 経口テストステロンエステル配合剤およびそれを含むテストステロン欠損を処置する方法
KR101679992B1 (ko) * 2015-12-31 2016-11-28 주식회사 유유제약 프로필렌글리콜 모노라우레이트를 포함하는 두타스테리드의 약학적 조성물 및 이의 제조 방법
US12290523B2 (en) 2016-02-24 2025-05-06 Eastern Virginia Medical School Formulation of long-acting levonorgestrel butanoate injectable depot suspension
CA3016542A1 (en) * 2016-03-02 2017-09-08 Board Of Regents, The University Of Texas System Formulations of testosterone and methods of treatment therewith
EP4596045A3 (en) 2016-03-28 2025-10-15 EirGen Pharma Ltd. Methods of vitamin d treatment
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US10646495B2 (en) * 2017-08-30 2020-05-12 Antares Pharma, Inc. Testosterone ester triglyceride formulations
CA3073527A1 (en) 2017-09-12 2019-03-21 Academic Pharmaceuticals, Inc. Metolazone emulsion formulation
WO2019055550A2 (en) * 2017-09-12 2019-03-21 Jina Pharmaceuticals, Inc. METHODS FOR PREPARING COMPOSITIONS CONTAINING THYMOQUINONE
WO2019087696A1 (ja) * 2017-11-01 2019-05-09 富士フイルム株式会社 経口医薬組成物
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
KR102051808B1 (ko) 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
UY38386A (es) * 2018-09-25 2020-04-30 Tolmar Int Ltd Sistema de suministro de polímero líquido para la administración prolongada de fármacos
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
WO2020210501A1 (en) * 2019-04-12 2020-10-15 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with anti-hypertensive agents
US12403146B2 (en) 2019-10-30 2025-09-02 Marius Pharmaceuticals, Inc. Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment
CN115052606A (zh) 2020-02-05 2022-09-13 戴尔诺有限公司 包含睾酮的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CA3091554A1 (en) * 2020-08-28 2022-02-28 Triple Hair Inc. Formulations for reducing hair loss and/or increasing hair regrowth
WO2022094817A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
CA3200755A1 (en) * 2020-12-19 2022-06-23 Mahesh Kandula A pharmaceutical composition comprising fexofenadine, famotidine and melatonin
KR20230161551A (ko) * 2022-05-18 2023-11-28 부광약품 주식회사 제제학적으로 안정성이 향상된 연질 캡슐

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH399447A (de) * 1961-04-14 1965-09-30 Ciba Geigy Verfahren zur Herstellung eines neuen Steroid-Hormon-Esters
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
FR1578974A (pl) 1968-05-16 1969-08-22
NL189235C (nl) 1974-02-28 1993-02-16 Akzo Nv Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
US4147783A (en) * 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US4572915A (en) * 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
GB8903804D0 (en) 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
WO1992018147A1 (en) 1991-04-19 1992-10-29 Affinity Biotech, Inc. Convertible microemulsion formulations
ATE144137T1 (de) 1991-07-26 1996-11-15 Smithkline Beecham Corp W/o mikroemulsionen
US5605929A (en) * 1992-05-27 1997-02-25 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
JPH08505367A (ja) 1992-10-16 1996-06-11 スミスクライン・ビーチャム・コーポレイション 医薬用エマルジョン組成物
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6312704B1 (en) 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
CN1140058A (zh) * 1996-03-29 1997-01-15 中国科学院成都有机化学研究所 一种雄性激素缓释微球粉针剂及其制备方法和用途
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
EP0913191A4 (en) 1996-05-23 1999-11-17 Taisho Pharmaceutical Co Ltd Microemulsion
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
KR20000070757A (ko) 1997-02-07 2000-11-25 에버트 챨스 디 테스토스테론 결핍증이 나타나는 여성에게 테스토스테론을 보충하는 방법 및 이에 이용되는 조성물
CA2287442A1 (en) 1997-04-18 1998-10-29 Taisho Pharmaceutical Co., Ltd. Microemulsion
US20030044434A1 (en) 1997-07-29 2003-03-06 Ping Gao Self-emulsifying formulation for lipophilic compounds
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
AU1508899A (en) 1997-12-02 1999-06-16 Chong Kun Dang Corporation Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US6013665A (en) * 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
CA2268211A1 (en) * 1998-04-13 1999-10-13 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
FR2782006B1 (fr) 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
DE69942205D1 (de) 1998-08-13 2010-05-12 Cima Labs Inc Microemulsionen als feste dosisformen zur oralen verabreichung
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
RU2246296C2 (ru) 1999-04-01 2005-02-20 Акцо Нобель Н.В. Композиция, включающая ундеканоат тестостерона и касторовое масло
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020102301A1 (en) 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US7025979B2 (en) * 2000-02-15 2006-04-11 Schering Ag Male contraceptive formulation comprising norethisterone
WO2001087316A2 (en) 2000-05-15 2001-11-22 Braswell, Glenn, A. Composition and method for increasing testosterone levels
AU2001271491A1 (en) * 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6623765B1 (en) 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
MXPA03001147A (es) 2000-08-23 2003-10-06 Akzo Nobel Nv Nueva formulacion de ester de testosterona para uso humano.
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
IL161047A0 (en) 2001-09-27 2004-08-31 Applied Research Systems Pyrazole derivatives for increasing endogenous testosterone levels
US6665880B2 (en) * 2001-11-01 2003-12-23 Kimberly-Clark Worldwide, Inc. Protective garments with glove flaps
US20050129718A1 (en) 2001-12-20 2005-06-16 Sherman Bernard C. Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
US20040002445A1 (en) * 2002-03-28 2004-01-01 Rajneesh Taneja Enhancement of endogenous gonadotropin production
US20030186892A1 (en) * 2002-03-28 2003-10-02 Rajneesh Taneja Enhancement of endogenous gonadotropin production
US20050287203A1 (en) * 2002-05-08 2005-12-29 Nijs De H Formulation comprising testosteron undecanoate and castor oil
EP1545477A4 (en) * 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
CA2505951A1 (en) * 2002-11-14 2004-05-27 Shear/Kershman Laboratories, Inc Oral testosterone delivery system with improved sustained release
US20040115287A1 (en) 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20050100608A1 (en) 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
DE602004032347D1 (de) 2003-07-31 2011-06-01 Debiotech Sa System zur durchführung von flüssigkeitsverabreichung in der peritonealdialyse
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US7138389B2 (en) * 2004-02-09 2006-11-21 University Of Washington Oral androgen therapy using modulators of testosterone bioavailability
US20050233970A1 (en) 2004-03-23 2005-10-20 Praecis Pharmaceuticals, Inc. Methods for treating long QT syndrome
JP5513713B2 (ja) 2004-08-04 2014-06-04 カムルス エービー 非層状分散を生じる組成物
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
DE102005015128B4 (de) 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
CN1686143A (zh) 2005-04-04 2005-10-26 浙江大学 十一酸睾酮自乳化软胶囊组合物及制备方法
US20080317850A1 (en) * 2005-04-08 2008-12-25 Ernest Alan Hewitt Buccal Delivery System
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2006113505A2 (en) 2005-04-15 2006-10-26 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US7400031B2 (en) * 2005-09-19 2008-07-15 International Business Machines Corporation Asymmetrically stressed CMOS FinFET
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
US8771233B2 (en) 2008-12-16 2014-07-08 Atsushi Watanabe Medication administering device
US20140288039A1 (en) 2009-01-08 2014-09-25 Lipocine Inc. Lipobalanced long chain testosterone prodrugs for oral delivery
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20130225544A1 (en) 2009-01-08 2013-08-29 Lipocine Inc. Lipobalanced long chain testosterone esters for oral delivery
EP2229936B1 (en) 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
US20130303495A1 (en) 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
PL2519230T3 (pl) 2009-12-31 2019-05-31 Marius Pharmaceuticals Llc Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
US20110263552A1 (en) 2009-12-31 2011-10-27 Sov Therapeutics Modulation of side effect profile of 5-alpha reductase inhibitor therapy
SG184540A1 (en) 2010-04-12 2012-11-29 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
US8367103B2 (en) 2010-09-27 2013-02-05 Bardani Frank M Oral testosterone composition
US20120135074A1 (en) 2010-11-30 2012-05-31 Chandrashekar Giliyar High-Strength Testosterone Undecanoate Compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20140309202A1 (en) 2010-11-30 2014-10-16 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2014521752A (ja) 2011-08-18 2014-08-28 モノソル・アールエックス・エルエルシー ステロイドホルモンの送達システムおよびその調製方法
WO2014080282A2 (en) 2012-11-22 2014-05-30 Trimel Biopharma Srl One-and two-point titration methods to determine daily treatment regimens to treat hypogonadism or male testosterone deficiency with an intranasal testosterone bio-adhesive gel, and primary and secondary efficacy and safety endpoints
CA2905703A1 (en) 2013-03-15 2014-09-18 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
EP3157508B1 (en) 2014-06-19 2020-12-09 Solural Pharma Aps Solid oral dosage form of lipophilic compounds
DK3185872T3 (da) 2014-08-28 2021-06-21 Univ Texas Formulering af testosteron og metoder til behandling hermed
WO2016049382A1 (en) 2014-09-24 2016-03-31 Lipocine Inc. Compositions and their use in oral dosing regimens
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20170319596A1 (en) 2015-11-10 2017-11-09 Lipocine Inc. Methods for improving quality of life or sexual domain function and composition useful in the methods
WO2017120592A1 (en) 2016-01-08 2017-07-13 Western University Of Health Sciences Proliposomal testosterone undecanoate formulations
CA3016542A1 (en) 2016-03-02 2017-09-08 Board Of Regents, The University Of Texas System Formulations of testosterone and methods of treatment therewith
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
JP2020500864A (ja) 2016-11-30 2020-01-16 リポカイン インコーポレーテッド 経口トリデカン酸テストステロン療法
WO2018213772A1 (en) 2017-05-18 2018-11-22 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
KR20230031370A (ko) 2017-06-12 2023-03-07 레이크우드 아메덱스, 인크. 비스포스포신 겔 제제 및 이의 용도
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
WO2020059512A1 (ja) 2018-09-18 2020-03-26 パナソニックＩｐマネジメント株式会社 扁平型ブラシ付コアレスモータ
US20200197412A1 (en) 2018-12-20 2020-06-25 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency

Also Published As

Publication number Publication date
US20200046733A1 (en) 2020-02-13
KR20130119518A (ko) 2013-10-31
JP2013121986A (ja) 2013-06-20
US8241664B2 (en) 2012-08-14
EP2985026B1 (en) 2022-08-03
US20130022674A1 (en) 2013-01-24
HUE061300T2 (hu) 2023-06-28
US20150343072A1 (en) 2015-12-03
JP5778705B2 (ja) 2015-09-16
JP2016074677A (ja) 2016-05-12
JP6251713B2 (ja) 2017-12-20
KR20130124414A (ko) 2013-11-13
US11331325B2 (en) 2022-05-17
US20180021351A1 (en) 2018-01-25
US11179402B2 (en) 2021-11-23
ES2930658T3 (es) 2022-12-20
US20230165878A1 (en) 2023-06-01
US20140249124A1 (en) 2014-09-04
RU2007142204A (ru) 2009-05-20
WO2006113505A2 (en) 2006-10-26
EP2985026A1 (en) 2016-02-17
EP1871384A2 (en) 2008-01-02
US20180021350A1 (en) 2018-01-25
KR101382725B1 (ko) 2014-04-08
CA2604943A1 (en) 2006-10-26
AU2006236564A1 (en) 2006-10-26
US20180028542A1 (en) 2018-02-01
AU2006236564A2 (en) 2006-10-26
US20190070196A1 (en) 2019-03-07
KR20080009201A (ko) 2008-01-25
KR101432466B1 (ko) 2014-08-21
AU2006236564B2 (en) 2011-02-17
EP2979699A1 (en) 2016-02-03
US20160000806A1 (en) 2016-01-07
US8828428B1 (en) 2014-09-09
RU2429850C2 (ru) 2011-09-27
US20140011789A1 (en) 2014-01-09
WO2006113505A3 (en) 2008-01-17
BRPI0607549A2 (pt) 2009-09-15
RU2623206C2 (ru) 2017-06-22
DK2985026T3 (da) 2022-10-31
JP5887044B2 (ja) 2016-03-16
RU2011119796A (ru) 2012-11-27
US20150343073A1 (en) 2015-12-03
US20180071311A1 (en) 2018-03-15
US20180078566A1 (en) 2018-03-22
CA2604943C (en) 2013-09-17
US20150343074A1 (en) 2015-12-03
JP2008537960A (ja) 2008-10-02
US8778917B2 (en) 2014-07-15
US20140296199A1 (en) 2014-10-02
US20250120983A1 (en) 2025-04-17
PT2985026T (pt) 2022-11-03
AU2011201422A1 (en) 2011-04-14
US20080317844A1 (en) 2008-12-25
EP1871384A4 (en) 2012-01-25
AU2011201422B2 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
PT2985026T (pt) Sistemas de distribuição farmacêuticos para fármacos hidrófobos e composições compreendendo os mesmos
EP1976492B8 (en) Drug delivery systems comprising weakly basic drugs and organic acids
IL185390A (en) A solid dosage form
GB2442875B (en) Regulated drug delivery system
IL179835A0 (en) Pharmaceutical compositions containing amphotericin b and delivery systems containing the same
PL3984528T3 (pl) Kompozycje farmaceutyczne zawierające nilotynib
IL194429A0 (en) Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
IL186162A0 (en) An aerosolized medicament containing amikacin and systems and devices for delivering the same
ZA200901110B (en) Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage from containing same
IL227899A0 (en) Mixing properties for a drug release system
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
IL203898A0 (en) Cdca1 peptide and pharmaceutical agent comprising the same
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
EP1895937A4 (en) STENT DISTRIBUTION AND GUIDANCE WIRE SYSTEMS
EP1858483A4 (en) SYSTEM FOR THE DELIVERY OF MULTIPLE MEDICAMENTS
ZA200807348B (en) Dosage aerosols for the administration of pharmaceutical preparations
IL197732A0 (en) Packaging system for pharmaceutical compositions for intravenous administration and kits comprising the same
GB0715493D0 (en) Delivery systems for solubilising water-insoluble pharmaceutical active ingredients
GB0614586D0 (en) Pharmaceutical Formulation
EP1858493A4 (en) SYSTEM FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
ZA200901366B (en) Drug delivery systems comprising solid solutions of weakly basic drugs
IL189827A0 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
GB0515363D0 (en) Drug delivery system
IL185561A0 (en) Microject devices and methods for drug delivery
GB0401008D0 (en) Drug delivery system